Find your next paid study

Memorial Sloan Kettering Cancer CenterNCT04410796

~$10 – $6,250

Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+8 more

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properti…

Novartis PharmaceuticalsNCT07006727

Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Chronic Myelogenous Leukemia (CML)+3 more

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transpl…

Memorial Sloan Kettering Cancer CenterNCT05884333

~$10 – $6,250

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors t…

CancerAdvanced CancerLocally Advanced Carcinoma+8 more

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various …

Angiex, Inc.NCT06440005

Advanced Solid TumorMetastatic Solid TumorGastric Adenocarcinoma+3 more

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants…

Kyowa Kirin Co., Ltd.NCT06266299

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response …

Non-small Cell Lung CancerColorectal CancerBreast Cancer

Guardant Health, Inc.NCT05935384

~$10 – $1,050

Non-small Cell Lung Cancer

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated …

Genentech, Inc.NCT04302025

Phase 3

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when gi…

Non-small Cell Lung Cancer

Merck Sharp & Dohme LLCNCT07190248

Phase 3

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

National Cancer Institute (NCI)NCT04269902

~$10 – $5,625

Acute Lymphoblastic LeukemiaB-All

A Phase II Study to Examine the Impact of CD22 CAR T-cells to Extend the Duration of Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from …

National Cancer Institute (NCI)NCT07328503

~$10 – $5,625

Advanced/Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small Cell LungNon-Small Cell Lung Cancer

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanc…